ZA200904175B - Imidazole derivatives as kinesin spindle protein inhibitors (EG-5) - Google Patents

Imidazole derivatives as kinesin spindle protein inhibitors (EG-5)

Info

Publication number
ZA200904175B
ZA200904175B ZA200904175A ZA200904175A ZA200904175B ZA 200904175 B ZA200904175 B ZA 200904175B ZA 200904175 A ZA200904175 A ZA 200904175A ZA 200904175 A ZA200904175 A ZA 200904175A ZA 200904175 B ZA200904175 B ZA 200904175B
Authority
ZA
South Africa
Prior art keywords
imidazole derivatives
protein inhibitors
spindle protein
kinesin spindle
kinesin
Prior art date
Application number
ZA200904175A
Other languages
English (en)
Inventor
Rustum Boyce
Eric Martin
Weibo Wang
Hong Yang
Paul A Barsanti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200904175B publication Critical patent/ZA200904175B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200904175A 2007-01-05 2009-06-15 Imidazole derivatives as kinesin spindle protein inhibitors (EG-5) ZA200904175B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88374007P 2007-01-05 2007-01-05

Publications (1)

Publication Number Publication Date
ZA200904175B true ZA200904175B (en) 2010-04-28

Family

ID=39577804

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200904175A ZA200904175B (en) 2007-01-05 2009-06-15 Imidazole derivatives as kinesin spindle protein inhibitors (EG-5)

Country Status (30)

Country Link
US (3) US7820646B2 (fr)
EP (1) EP2106399A2 (fr)
JP (1) JP2010515687A (fr)
KR (1) KR20090097210A (fr)
CN (1) CN101622247A (fr)
AR (1) AR064760A1 (fr)
AU (1) AU2008205169B2 (fr)
BR (1) BRPI0806264A2 (fr)
CA (1) CA2674318A1 (fr)
CL (1) CL2008000029A1 (fr)
CO (1) CO6561828A2 (fr)
CR (1) CR10879A (fr)
DO (1) DOP2009000169A (fr)
EA (1) EA200900924A1 (fr)
EC (1) ECSP099485A (fr)
GE (1) GEP20125415B (fr)
GT (1) GT200900192A (fr)
HN (1) HN2009001262A (fr)
MA (1) MA31080B1 (fr)
MX (1) MX2009007260A (fr)
NI (1) NI200900134A (fr)
NZ (1) NZ577727A (fr)
PE (1) PE20081850A1 (fr)
SM (1) SMP200900065B (fr)
SV (1) SV2009003325A (fr)
TN (1) TN2009000287A1 (fr)
TW (1) TW200836722A (fr)
UA (1) UA97821C2 (fr)
WO (1) WO2008086122A2 (fr)
ZA (1) ZA200904175B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252832B2 (en) 2007-12-14 2012-08-28 Novartis Ag Kinesin inhibitors as cancer therapeutics
CN103153970A (zh) * 2010-04-15 2013-06-12 诺瓦提斯公司 作为ksp抑制剂的*唑和噻唑化合物
JP2013523867A (ja) 2010-04-15 2013-06-17 ノバルティス アーゲー Ksp阻害剤としてのトリアゾール化合物
EP2390247A1 (fr) 2010-05-26 2011-11-30 Netherlands Organisation for Scientific Research (Advanced Chemical Technologies for Sustainability) Préparation de caprolactone, caprolactam, 2,5-tétrahydrofuranne diméthanol, 1,6-héxanediol ou 1,2,6-hexanetriol à partir de 5-hydroxymethyl-2-furfuraldehyde
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
JP2016516035A (ja) * 2013-03-15 2016-06-02 ノバルティス アーゲー 細胞増殖阻害剤およびそれらのコンジュゲート
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
KR102329024B1 (ko) * 2013-12-23 2021-11-19 바이엘 파마 악티엔게젤샤프트 키네신 스핀들 단백질(ksp)과의 항체 약물 접합체 (adcs)
EP3310440A1 (fr) * 2015-06-22 2018-04-25 Bayer Pharma Aktiengesellschaft Conjugués anticorps-médicament (adc) et conjugués lieur-promédicament (apdc) à groupes enzymatiquement clivables
CN105330657B (zh) * 2015-12-08 2019-05-21 华润双鹤药业股份有限公司 5-氯-2-[5-(r)-甲基-1,4-二氮杂环庚烷-1-]苯并恶唑的制备方法
CN105367506B (zh) * 2015-12-08 2021-02-05 华润双鹤药业股份有限公司 手性高哌嗪环的制备方法
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ksp阻害剤および抗cd123抗体を含む特異的抗体-薬物-コンジュゲート(adc)
CA3047522A1 (fr) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Conjugues anticorps-principe actif (adc) specifiques renfermant des inhibiteurs de ksp
MX2019007641A (es) 2016-12-21 2019-09-09 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
BR112020025718A2 (pt) 2018-06-18 2021-04-06 Bayer Aktiengesellschaft Conjugados de ligante/agente ativo direcionados contra cxcr5, tendo aglutinantes enzimaticamente cliváveis e perfil de atividade melhorado

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2550959C3 (de) 1975-11-13 1980-12-04 Hoechst Ag, 6000 Frankfurt Tetrazolyl-imidazole und Tetrazolyl--benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB2157285B (en) 1984-04-11 1987-10-28 Erba Farmitalia 1h, 7h-pyrazolo1, 5-a pyrimidine-7-one derivatives and process for their preparation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5859012A (en) * 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998027108A2 (fr) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Nouveaux composes amide
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
US6172087B1 (en) 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
WO2000059887A1 (fr) 1999-04-02 2000-10-12 Neurogen Corporation Derives d'aminoalkyle-imidazole condenses aryles et heteroaryles et leur utilisation comme antidiabetiques
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US20040132788A1 (en) 1999-10-11 2004-07-08 Chabrier De Lassauniere Pierre-Etienne Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI283577B (en) 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
BR0015110A (pt) 1999-10-27 2002-07-02 Cytokinetics Inc Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2001083575A1 (fr) 2000-05-02 2001-11-08 Advanced Syntech, Llc A Kentucky Limited Liability Corporation Nouvelle matrice de support solide destinee a la preparation de composes heterocycles a haute fonctionnalite
US6951948B2 (en) 2000-06-05 2005-10-04 Ortho-Mcneil Pharmaceutical, Inc. Method for synthesis of substituted azole libraries
US6683191B2 (en) 2000-06-05 2004-01-27 Ortho-Mcneil Pharmaceuticals, Inc. Method for synthesis of substituted azole libraries
KR20030020960A (ko) 2000-08-01 2003-03-10 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 이미다졸일 유도체
AU2001296799A1 (en) 2000-10-06 2002-04-15 Neurogen Corporation Benzimidazole and indole derivatives as crf receptor modulators
EP1341768A1 (fr) 2000-12-07 2003-09-10 AstraZeneca AB Composes therapeutiques de benzimidazole
WO2002083143A1 (fr) 2000-12-11 2002-10-24 Tularik Inc. Antagonistes de cxcr3
EP1351671A1 (fr) 2001-01-19 2003-10-15 Cytokinetics, Inc. Inhibiteurs triphenylmethane de la kinesine
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
EP1444209A4 (fr) 2001-11-07 2005-02-16 Merck & Co Inc Inhibiteurs de la kinesine mitotique
WO2003043995A1 (fr) 2001-11-20 2003-05-30 Cytokinetics, Inc. Procede de racemisation de quinazolinones chirales
DE60231439D1 (de) 2001-12-06 2009-04-16 Merck & Co Inc Mitotische kinesinhemmer
CA2467726A1 (fr) 2001-12-06 2003-06-19 Merck & Co., Inc. Inhibiteurs mitotiques de la kinesine
ES2291543T3 (es) 2001-12-06 2008-03-01 MERCK & CO., INC. Inhibicion de kinesina mitotica.
DE60234278D1 (de) 2001-12-06 2009-12-17 Merck & Co Inc Mitotische kinesin-hemmer
AU2002363960B2 (en) 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
CA2472470A1 (fr) 2002-01-10 2003-07-24 Neurogen Corporation Ligands recepteurs de l'hormone de concentration de la melanine: analogues de benzoimidazole substitue
CA2475879A1 (fr) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis de quinazolinones
ATE448207T1 (de) 2002-03-08 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10211770A1 (de) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
MXPA04010240A (es) 2002-04-17 2005-06-08 Cytokinetics Inc Compuestos, composiciones y metodos.
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
AU2003245259A1 (en) 2002-05-02 2003-11-17 Neurogen Corporation Substituted imidazole derivatives: gabaa receptor ligands
US6982268B2 (en) 2002-05-08 2006-01-03 Neurogen Corporation Substituted imidazolylmethyl pyridine and pyrazine derivatives GABAA receptor ligands
JP2005530785A (ja) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
PL373412A1 (en) 2002-05-09 2005-08-22 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods of their use for treating cellular proliferative diseases
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
AU2003237881A1 (en) 2002-05-17 2003-12-02 Neurogen Corporation Substituted ring-fused imidazole derivates: gabaa receptor ligands
US7038048B2 (en) 2002-05-23 2006-05-02 Cytokinetics, Inc. 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
EP1509507A4 (fr) * 2002-05-23 2006-09-13 Merck & Co Inc Inhibiteurs de kinesine mitotique
US7041676B2 (en) 2002-06-14 2006-05-09 Cytokinetics, Inc. Compounds, compositions, and methods
CA2486215A1 (fr) 2002-06-14 2003-12-24 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
PL374190A1 (en) 2002-06-14 2005-10-03 Merck & Co, Inc. Mitotic kinesin inhibitors
WO2004004652A2 (fr) 2002-07-08 2004-01-15 Merck & Co., Inc. Site de liaison de la kinesine mitotique
DE60326248D1 (de) 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
JP2005536553A (ja) 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2004024086A2 (fr) 2002-09-13 2004-03-25 Cytokinetics, Inc. Composés, compositions et méthodes
CN100579579C (zh) 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
EP1560822B1 (fr) 2002-11-08 2006-08-09 Neurogen Corporation Derives de 4-imidazol-1-ylmethyl-pyrimidine en tant que ligands de recepteurs gabaa
AU2003299612A1 (en) * 2002-12-13 2004-07-09 Cytokinetics Compounds, compositions and methods
JP2006515886A (ja) 2003-01-17 2006-06-08 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
WO2004071448A2 (fr) 2003-02-12 2004-08-26 Transtech Pharma Inc. Derives d'azole substitues comme agents therapeutiques
US20080021079A1 (en) 2003-05-07 2008-01-24 Han-Jie Zhou Compounds, Compositions, and Methods
JP2007500746A (ja) 2003-05-15 2007-01-18 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
CN1809563A (zh) 2003-06-20 2006-07-26 希龙公司 吡啶并[1,2-a]嘧啶-4-酮化合物用作抗癌药
WO2005041888A2 (fr) * 2003-11-03 2005-05-12 Cytokinetics, Inc. Composes, compositions et methodes
CN1922151A (zh) 2004-02-12 2007-02-28 特兰斯泰克制药公司 取代的吡咯衍生物、组合物和使用方法
PT1732926E (pt) 2004-04-06 2009-04-03 Novartis Vaccines & Diagnostic Inibidores de cinesinas mitóticas
BRPI0509853A (pt) 2004-04-14 2007-10-09 Pfizer compostos de imidazol ligados a enxofre para o tratamento de hiv
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
AU2005245492A1 (en) 2004-05-21 2005-12-01 Novartis Vaccines And Diagnostics, Inc. Substituted quinoline derivatives as mitotic kinesin inhibitors
RU2427572C2 (ru) 2004-06-18 2011-08-27 Чирон Корпорейшн N-(1-(1-бензил-4-фенил-1н-имидазол-2-ил)-2,2-диметилпропил)бензамидные производные и родственные соединения в качестве ингибиторов кинезинового белка веретена (ksp) для лечения рака
EP2275412A1 (fr) 2004-10-19 2011-01-19 Novartis Vaccines and Diagnostics, Inc. Dérivés d'indole et de benzimidazole
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
GEP20125389B (en) 2006-11-13 2012-01-25 Novartis Ag Substituted pyrazole and triazole compounds as ksp inhibitors

Also Published As

Publication number Publication date
SV2009003325A (es) 2011-08-09
EP2106399A2 (fr) 2009-10-07
MA31080B1 (fr) 2010-01-04
SMAP200900065A (it) 2009-09-07
KR20090097210A (ko) 2009-09-15
NZ577727A (en) 2012-03-30
WO2008086122A2 (fr) 2008-07-17
US20120189623A1 (en) 2012-07-26
GEP20125415B (en) 2012-03-12
US7820646B2 (en) 2010-10-26
CL2008000029A1 (es) 2008-04-04
ECSP099485A (es) 2009-08-28
GT200900192A (es) 2010-06-24
TN2009000287A1 (en) 2010-12-31
CN101622247A (zh) 2010-01-06
TW200836722A (en) 2008-09-16
HN2009001262A (es) 2012-01-09
UA97821C2 (en) 2012-03-26
SMP200900065B (it) 2010-09-10
US20080207589A1 (en) 2008-08-28
AU2008205169B2 (en) 2012-02-02
AU2008205169A1 (en) 2008-07-17
JP2010515687A (ja) 2010-05-13
CR10879A (es) 2009-08-05
AR064760A1 (es) 2009-04-22
DOP2009000169A (es) 2009-08-31
BRPI0806264A2 (pt) 2011-08-30
PE20081850A1 (es) 2009-02-05
MX2009007260A (es) 2009-07-10
CO6561828A2 (es) 2012-11-15
EA200900924A1 (ru) 2009-12-30
CA2674318A1 (fr) 2008-07-17
WO2008086122A3 (fr) 2008-10-16
US20110003791A1 (en) 2011-01-06
NI200900134A (es) 2010-07-05

Similar Documents

Publication Publication Date Title
ZA200904175B (en) Imidazole derivatives as kinesin spindle protein inhibitors (EG-5)
EP2222674B8 (fr) Amino triazoles en tant qu'inhibiteurs pi3k
EP2057158B8 (fr) Dérivés de triazole en tant qu'inhibiteurs de kinase
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
HK1143367A1 (en) Quinazolin-oxime derivatives as hsp90 inhibitors hsp90 -
SI2201012T1 (sl) Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
PL2193133T3 (pl) Imidazolotiadiazole do stosowania jako inhibitory kinazy białkowej
IL194582A0 (en) Condensed imidazole derivatives as aromatase inhibitors
IL206416A0 (en) Benzofuropyrimidinones as protein kinase inhibitors
HK1133650A1 (en) Hydantoin derivatives used as mmp inhibitors
EP2200436A4 (fr) Pyrimidinyl-amines substituées en tant qu'inhibiteurs de la protéine kinase
HK1101823A1 (en) Imidazole derivatives used as tafia inhibitors
HK1151291A1 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
ZA201003125B (en) Imidazole derivatives
EP2336123A4 (fr) Composé hétérocyclique utilisé comme inhibiteur de la protéine kinase
IL201367A0 (en) 2 - morpholin - 4 - yl - pyrimidines as pi3k inhibitors
IL205148A0 (en) Novel imidazole derivatives
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
PL1937673T3 (pl) Pochodne imidazolu jako inhibitory TAFI-A
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
IL205149A0 (en) Novel imidazole derivatives
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
ZA201002519B (en) Novel imidazole derivatives